Selection Pressure on HIV-1 Envelope by Broadly Neutralizing Antibodies to the Conserved CD4-Binding Site
暂无分享,去创建一个
Richard T. Wyatt | John R. Mascola | Mark Connors | Hiromi Imamichi | Brandon F. Keele | George M. Shaw | J. Hoxie | J. Mascola | R. Wyatt | M. Connors | G. Shaw | B. Keele | N. Doria-Rose | Yuxing Li | Xueling Wu | H. Imamichi | Yuxing Li | Xueling Wu | James A. Hoxie | Sijy O'Dell | Nicole Doria-Rose | Charlene Wang | Zhongjia Yang | S. O’dell | Zhongjia Yang | Charlene Wang
[1] William R. Taylor,et al. The rapid generation of mutation data matrices from protein sequences , 1992, Comput. Appl. Biosci..
[2] R. Weiss,et al. Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization , 2012, The Journal of experimental medicine.
[3] Tongqing Zhou,et al. Mechanism of Human Immunodeficiency Virus Type 1 Resistance to Monoclonal Antibody b12 That Effectively Targets the Site of CD4 Attachment , 2009, Journal of Virology.
[4] Amanda M. Brown,et al. Selection for Neutralization Resistance of the Simian/Human Immunodeficiency Virus SHIVSF33A Variant In Vivo by Virtue of Sequence Changes in the Extracellular Envelope Glycoprotein That Modify N-Linked Glycosylation , 1999, Journal of Virology.
[5] Mark Connors,et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies , 2007, Nature Medicine.
[6] Susan Zolla-Pazner,et al. A Variable Region 3 (V3) Mutation Determines a Global Neutralization Phenotype and CD4-Independent Infectivity of a Human Immunodeficiency Virus Type 1 Envelope Associated with a Broadly Cross-Reactive, Primary Virus-Neutralizing Antibody Response , 2002, Journal of Virology.
[7] Mario Roederer,et al. Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing , 2011, Science.
[8] Richard T. Wyatt,et al. Breadth of Human Immunodeficiency Virus-Specific Neutralizing Activity in Sera: Clustering Analysis and Association with Clinical Variables , 2009, Journal of Virology.
[9] T. Kepler,et al. Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors , 2011, Journal of Virology.
[10] Dorothy M. Lang,et al. Selection for Human Immunodeficiency Virus Type 1 Envelope Glycosylation Variants with Shorter V1-V2 Loop Sequences Occurs during Transmission of Certain Genetic Subtypes and May Impact Viral RNA Levels , 2005, Journal of Virology.
[11] Martin A. Nowak,et al. Antibody neutralization and escape by HIV-1 , 2003, Nature.
[12] J. Sodroski,et al. Soluble CD4 and CD4-Mimetic Compounds Inhibit HIV-1 Infection by Induction of a Short-Lived Activated State , 2009, PLoS pathogens.
[13] H. Schuitemaker,et al. Longitudinal Analysis of Early HIV-1-Specific Neutralizing Activity in an Elite Neutralizer and in Five Patients Who Developed Cross-Reactive Neutralizing Activity , 2011, Journal of Virology.
[14] Y. Masuho,et al. Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus. , 1991, Virology.
[15] J. Overbaugh,et al. HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. , 2002, AIDS research and human retroviruses.
[16] D R Burton,et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. , 1994, Science.
[17] Tongqing Zhou,et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120 , 2007, Nature.
[18] Jamie K. Scott,et al. Identification and Characterization of a Peptide That Specifically Binds the Human, Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody b12 , 2001, Journal of Virology.
[19] Hanneke Schuitemaker,et al. Autologous Neutralizing Humoral Immunity and Evolution of the Viral Envelope in the Course of Subtype B Human Immunodeficiency Virus Type 1 Infection , 2008, Journal of Virology.
[20] Mario Roederer,et al. Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.
[21] A. Lapedes,et al. Timing the ancestor of the HIV-1 pandemic strains. , 2000, Science.
[22] J. Overbaugh,et al. Temporal analysis of HIV envelope sequence evolution and antibody escape in a subtype A-infected individual with a broad neutralizing antibody response. , 2010, Virology.
[23] J. Sodroski,et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.
[24] A. Caliendo. Human Immunodeficiency Virus Type 1 , 2007 .
[25] Xiping Wei,et al. Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2005, Journal of Virology.
[26] Tongqing Zhou,et al. Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 , 2010, Science.
[27] Lynn Morris,et al. Antibody Specificities Associated with Neutralization Breadth in Plasma from Human Immunodeficiency Virus Type 1 Subtype C-Infected Blood Donors , 2009, Journal of Virology.
[28] Bette T. Korber,et al. Envelope-Constrained Neutralization-Sensitive HIV-1 After Heterosexual Transmission , 2004, Science.
[29] Lynn Morris,et al. Limited Neutralizing Antibody Specificities Drive Neutralization Escape in Early HIV-1 Subtype C Infection , 2009, PLoS pathogens.
[30] Terri Wrin,et al. Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm , 2009, Journal of Virology.
[31] B. Korber,et al. Deciphering Human Immunodeficiency Virus Type 1 Transmission and Early Envelope Diversification by Single-Genome Amplification and Sequencing , 2008, Journal of Virology.
[32] J. Albert,et al. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. , 1990, AIDS.
[33] J. Felsenstein,et al. A simulation comparison of phylogeny algorithms under equal and unequal evolutionary rates. , 1994, Molecular biology and evolution.
[34] Barney S. Graham,et al. Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 , 2011, Journal of Virology.
[35] Lynn Morris,et al. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? , 2009, Nature Medicine.
[36] Holly Janes,et al. Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies , 2009, Journal of Virology.
[37] J. Sodroski,et al. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. , 1998, Science.
[38] Q. Sattentau,et al. Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals , 2010, PloS one.
[39] Pham Phung,et al. Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.
[40] F. Pereyra,et al. Continuous Viral Escape and Selection by Autologous Neutralizing Antibodies in Drug-Naïve Human Immunodeficiency Virus Controllers , 2008, Journal of Virology.
[41] Graham J. Etherington,et al. Recombination Analysis Tool (RAT): a program for the high-throughput detection of recombination , 2005, Bioinform..
[42] B. Korber,et al. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. , 1992, Science.
[43] J. Sodroski,et al. Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. , 2008, Structure.
[44] J. Overbaugh,et al. Gender differences in HIV-1 diversity at time of infection , 2000, Nature Medicine.
[45] Michael G Hudgens,et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. , 2005, The Journal of infectious diseases.
[46] G Himmler,et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 , 1993, Journal of virology.
[47] Ron Diskin,et al. Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.
[48] L. Morris,et al. The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection , 2011, Journal of Virology.
[49] L. Morris,et al. Potent and Broad Neutralization of HIV-1 Subtype C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the V2 Loop , 2011, Journal of Virology.
[50] D. Richman,et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[51] H. Kishino,et al. Evaluation of the maximum likelihood estimate of the evolutionary tree topologies from DNA sequence data, and the branching order in hominoidea , 1989, Journal of Molecular Evolution.
[52] S. Gnanakaran,et al. Escape from Autologous Neutralizing Antibodies in Acute/Early Subtype C HIV-1 Infection Requires Multiple Pathways , 2009, PLoS pathogens.
[53] Bette T. Korber,et al. Detecting hypermutations in viral sequences with an emphasis on G A hypermutation , 2000, Bioinform..
[54] Lynn Morris,et al. Broad Neutralization of Human Immunodeficiency Virus Type 1 Mediated by Plasma Antibodies against the gp41 Membrane Proximal External Region , 2009, Journal of Virology.
[55] Pham Phung,et al. Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.
[56] J. Margolick,et al. Consistent Viral Evolutionary Changes Associated with the Progression of Human Immunodeficiency Virus Type 1 Infection , 1999, Journal of Virology.
[57] Rodrigo Lopez,et al. Clustal W and Clustal X version 2.0 , 2007, Bioinform..
[58] E. C. Ritchie,et al. Gender Differences , 1981, Language in Society.
[59] Roy E. Byington,et al. Quantitative Assays for Virus Infectivity , 1990 .
[60] Daniel H. Huson,et al. Dendroscope: An interactive viewer for large phylogenetic trees , 2007, BMC Bioinformatics.
[61] J. Sodroski,et al. Loss of a Single N-Linked Glycan Allows CD4-Independent Human Immunodeficiency Virus Type 1 Infection by Altering the Position of the gp120 V1/V2 Variable Loops , 2001, Journal of Virology.
[62] Dennis R. Burton,et al. A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals , 2010, PLoS pathogens.
[63] J. Felsenstein,et al. A Hidden Markov Model approach to variation among sites in rate of evolution. , 1996, Molecular biology and evolution.
[64] Xiping Wei,et al. Evidence for Potent Autologous Neutralizing Antibody Titers and Compact Envelopes in Early Infection with Subtype C Human Immunodeficiency Virus Type 1 , 2006, Journal of Virology.
[65] John P. Moore,et al. Increased CCR5 Affinity and Reduced CCR5/CD4 Dependence of a Neurovirulent Primary Human Immunodeficiency Virus Type 1 Isolate , 2002, Journal of Virology.
[66] Robert C. Edgar,et al. MUSCLE: a multiple sequence alignment method with reduced time and space complexity , 2004, BMC Bioinformatics.
[67] Xuesong Yu,et al. Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 Infection , 2008, Journal of Virology.
[68] J. Overbaugh,et al. Neutralization Escape Variants of Human Immunodeficiency Virus Type 1 Are Transmitted from Mother to Infant , 2006, Journal of Virology.
[69] J. Sodroski,et al. Contribution of Intrinsic Reactivity of the HIV-1 Envelope Glycoproteins to CD4-Independent Infection and Global Inhibitor Sensitivity , 2011, PLoS pathogens.
[70] David Posada,et al. MODELTEST: testing the model of DNA substitution , 1998, Bioinform..
[71] Douglas D. Richman,et al. Dissecting the Neutralizing Antibody Specificities of Broadly Neutralizing Sera from Human Immunodeficiency Virus Type 1-Infected Donors , 2007, Journal of Virology.
[72] Barbra A. Richardson,et al. Neutralization Escape Variants of Human Immunodeficiency Virus Type 1 Are Transmitted from Mother to Infant , 2006, Journal of Virology.
[73] Temporal Analysis , 2014, Encyclopedia of Social Network Analysis and Mining.
[74] Feng Gao,et al. Recurrent Signature Patterns in HIV-1 B Clade Envelope Glycoproteins Associated with either Early or Chronic Infections , 2011, PLoS pathogens.
[75] John R. Mascola,et al. Analysis of Neutralization Specificities in Polyclonal Sera Derived from Human Immunodeficiency Virus Type 1-Infected Individuals , 2008, Journal of Virology.
[76] Robert C. Edgar,et al. MUSCLE: multiple sequence alignment with high accuracy and high throughput. , 2004, Nucleic acids research.
[77] A. Trkola,et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.
[78] L. Morris,et al. The C3-V4 Region Is a Major Target of Autologous Neutralizing Antibodies in Human Immunodeficiency Virus Type 1 Subtype C Infection , 2007, Journal of Virology.
[79] J. Overbaugh,et al. Human Immunodeficiency Virus Type 1 V1-V2 Envelope Loop Sequences Expand and Add Glycosylation Sites over the Course of Infection, and These Modifications Affect Antibody Neutralization Sensitivity , 2006, Journal of Virology.
[80] A. Sethi,et al. The B Cell Response Is Redundant and Highly Focused on V1V2 during Early Subtype C Infection in a Zambian Seroconverter , 2010, Journal of Virology.
[81] Alan S. Perelson,et al. High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men , 2010, PLoS pathogens.
[82] G. Gottlieb,et al. HIV-1 Envelope Subregion Length Variation during Disease Progression , 2010, PLoS pathogens.
[83] Hui Li,et al. Neutralizing Antibody Responses in Acute Human Immunodeficiency Virus Type 1 Subtype C Infection , 2007, Journal of Virology.
[84] Yang Liu,et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[85] Xi Chen,et al. Isolation of a Monoclonal Antibody That Targets the Alpha-2 Helix of gp120 and Represents the Initial Autologous Neutralizing-Antibody Response in an HIV-1 Subtype C-Infected Individual , 2011, Journal of Virology.
[86] Kenneth H Mayer,et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. , 2005, The Journal of infectious diseases.
[87] Hui Li,et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection , 2008, Proceedings of the National Academy of Sciences.